Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4256984 in Sporadic Amyotrophic Lateral Sclerosis
NCT07100119Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised trial in amyotrophic lateral sclerosis (ALS) comparing LY4256984 (Cohorts 1-3) with Placebo (2 arms). Primary endpoint: Adverse Events at Day 253. Started Aug 2025; status: recruiting.
02
Drugs
LY4256984
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07100119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100119.